Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease

Background  Complementary and alternative medicine (CAM) use among inflammatory bowel disease (IBD) patients is common. We characterised CAM utilisation and assessed its impact on medical adherence in the IBD population.

[1]  A. Kornbluth,et al.  Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence , 2011, Inflammatory bowel diseases.

[2]  F. Nagy,et al.  Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. , 2010, Journal of Crohn's & colitis.

[3]  Joseph Finkelstein,et al.  Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT)* , 2010, Inflammatory bowel diseases.

[4]  S. Brant,et al.  Patient trust‐in‐physician and race are predictors of adherence to medical management in inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[5]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[6]  G. Rubin,et al.  Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies , 2008, Alimentary pharmacology & therapeutics.

[7]  G. Lip,et al.  Bmc Complementary and Alternative Medicine Self-care and Adherence to Medication: a Survey in the Hypertension Outpatient Clinic , 2008 .

[8]  S. Willich,et al.  Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease , 2006, BMC complementary and alternative medicine.

[9]  S. Kane.  Systematic review: adherence issues in the treatment of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[10]  D. Rampton,et al.  Review article: complementary and alternative therapies for inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[11]  M. Verhoef,et al.  Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[12]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[13]  C. Reisen,et al.  Complementary and alternative medicine and adherence to care among HIV-positive Latino gay and bisexual men , 2005, AIDS care.

[14]  Kathleen King,et al.  Medication Adherence and Associated Hemoglobin A1c in Type 2 Diabetes , 2004, The Annals of pharmacotherapy.

[15]  C. Bernstein,et al.  Predictors of Alternative and Complementary Medicine Use in Inflammatory Bowel Disease: Do Measures of Conventional Health Care Utilization Relate to Use? , 2004, American Journal of Gastroenterology.

[16]  M. Verhoef,et al.  Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey , 2003, American Journal of Gastroenterology.

[17]  C. Bernstein,et al.  An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease , 1999, American Journal of Gastroenterology.

[18]  M. Verhoef,et al.  Complementary and alternative medicine use by patients with inflammatory bowel disease: An Internet survey. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[19]  J. Mccombs,et al.  Compliance with Sulfonylureas in a Health Maintenance Organization: A Pharmacy Record–Based Study , 1999, The Annals of pharmacotherapy.

[20]  R. Kessler,et al.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. , 1998, JAMA.

[21]  J. Mccombs,et al.  Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. , 1998, The American journal of managed care.

[22]  J. Astin.  Why patients use alternative medicine: results of a national study. , 1998, JAMA.

[23]  M. Verhoef,et al.  Complementary medicine use by patients with inflammatory bowel disease , 1998, American Journal of Gastroenterology.

[24]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[25]  R. Kessler,et al.  Unconventional medicine in the United States. Prevalence, costs, and patterns of use. , 1993, The New England journal of medicine.

[26]  Robert F. Dedrick,et al.  Development of the Trust in Physician Scale: A Measure to Assess Interpersonal Trust in Patient-Physician Relationships , 1990, Psychological reports.

[27]  M. Verhoef,et al.  Use of alternative medicine by patients attending a gastroenterology clinic. , 1990, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[28]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[29]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[30]  D. Cockburn,et al.  Complementary medicine. , 2004, Clinical & experimental optometry.

[31]  A. Thomson.  Patient nonadherence to medication in inflammatory bowel disease. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[32]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.